Pacific Biosciences Of California traded at $4.57 this Wednesday June 29th, decreasing $0.29 or 5.97 percent since the previous trading session. Looking back, over the last four weeks, Pacific Biosciences Of California lost 18.83 percent. Over the last 12 months, its price fell by 86.93 percent. Looking ahead, we forecast Pacific Biosciences Of California to be priced at 5.46 by the end of this quarter and at 5.03 in one year, according to Trading Economics global macro models projections and analysts expectations.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
Agilent 117.90 0.84 0.72% -20.24%
Accelerate Diagnostics 0.86 -0.11 -11.01% -89.29%
Bruker 62.95 0.40 0.64% -17.15%
Danaher 252.86 0.98 0.39% -5.78%
Standard Biotools Inc 1.61 -0.14 -8.00% -73.86%
General Electric 63.69 -2.19 -3.32% -40.85%
Illumina 186.43 -1.00 -0.53% -60.60%
Myriad Genetics 18.44 0.03 0.16% -39.70%
NanoString Technologies 12.72 -0.58 -4.36% -80.37%
Pacific Biosciences Of California 4.57 -0.29 -5.97% -86.93%
PerkinElmer 142.28 0.95 0.67% -7.86%
Quidel 100.03 -0.78 -0.77% -21.92%
Roche Holding 319.65 2.10 0.66% -8.29%
Thermo Fisher Scientific 535.92 0.15 0.03% 5.18%
Waters 329.60 0.16 0.05% -4.63%

Indexes Price Day Year
USND 11178 -3.65 -0.03% -22.93%
US2000 1719 -19.47 -1.12% -25.59%

Pacific Biosciences Of California
Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company has developed its Single Molecule, Real-Time (SMRT) technology, which enables single molecule, real-time detection of nucleic acid sequences, to address many of the limitations of previous sequencing technologies. The Company’s products include the Sequel II and Sequel IIe instruments and SMRT Cell 8M, which together are capable of sequencing up to approximately eight million deoxyribonucleic acid (DNA) molecules simultaneously, and the previous generation Sequel instrument and Sequel SMRT Cell 1M, which together are capable of sequencing up to one million DNA molecules simultaneously. Its Sequel IIe System increases computational capacity and is designed to enable customers to generate PacBio HiFi reads.